You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data

Article metrics

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials in-progress
799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data

 

Online download statistics by month:

Online download statistics by month: November 2020 to August 2024

AbstractFullPdf
Nov 2020306034
Dec 202066010
Jan 20215604
Feb 202111806
Mar 2021102010
Apr 202164010
May 202131014
Jun 2021007
Jul 20211014
Aug 20210017
Sep 20210014
Oct 202184023
Nov 2021106015
Dec 20216206
Jan 202294010
Feb 20225609
Mar 2022106016
Apr 2022104012
May 2022140013
Jun 20228008
Jul 20227806
Aug 202211408
Sep 20226808
Oct 20227002
Nov 20228805
Dec 20227007
Jan 20235002
Feb 20234402
Mar 20237405
Apr 20237208
May 20234006
Jun 20233601
Jul 20234205
Aug 202354013
Sep 20234404
Oct 202348011
Nov 20236603
Dec 20235404
Jan 20241600
Feb 202411802
Mar 20246409
Apr 20243002
May 20243803
Jun 20243908
Jul 202410003
Aug 20243103
Total31240382